Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience

Kharouf, Fadi; Kenig, Ariel; Bohbot, Emilie; Rubin, Limor; Peleg, Hagit; Shamriz, Oded

doi:10.55563/clinexprheumatol/970881

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they observed that the newly diagnosed patients displayed different demographic characteristics and more severe course of the disease than that observed before the pandemic, although the prognosis remained unchanged. They suggested that both the SARS-CoV-2 infection and SARS-Cov-2 mRNA vaccines could have been possible triggers for IIMs appearance (1). Their observation is surely interesting and in line with the common idea of a possible link between infections and the development of autoimmunity (2), particularly, between viruses and IIMs.…”

mentioning

confidence: 59%

Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison?

Cavagna

Ferro

Zanframundo

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

mentioning

confidence: 59%

Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison?

Cavagna

Ferro

Zanframundo

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

“…Recently, an increased incidence of IIMs was reported during the COVID-19 pandemic ( 33 , 34 ). It has been postulated that an overactive innate immune response to SARS-CoV-2 might contribute to the development and deterioration of autoimmune diseases.…”

Section: Discussionmentioning

confidence: 99%

Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19

Wu,

Wang,

Xie

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundData with fine granularity about COVID-19-related outcomes and risk factors were still limited in the idiopathic inflammatory myopathies (IIMs) population. This study aimed to investigate clinical factors associated with hospitalized and severe COVID-19 in patients with IIMs, particularly those gauged by myositis-specific antibodies.MethodsThis retrospective cohort study was conducted in the Renji IIM cohort in Shanghai, China, under an upsurge of SARS-CoV-2 omicron variant infections from December 2022 to January 2023. Clinical data were collected and analyzed by multivariable logistic regression to determine risk factors. High-dimensional flow cytometry analysis was performed to outline the immunological features.ResultsAmong 463 infected patients in the eligible cohort (n=613), 65 (14.0%) were hospitalized, 19 (4.1%) suffered severe COVID-19, and 10 (2.2%) died. Older age (OR=1.59/decade, 95% CI 1.18 to 2.16, p=0.003), requiring family oxygen supplement (2.62, 1.11 to 6.19, 0.028), patients with anti-synthetase syndrome (ASyS) (2.88, 1.12 to 7.34, 0.027, vs. other dermatomyositis), higher IIM disease activity, and prednisone intake >10mg/day (5.59, 2.70 to 11.57, <0.001) were associated with a higher risk of hospitalization. Conversely, 3-dose inactivated vaccination reduced the risk of hospitalization (0.10, 0.02 to 0.40, 0.001, vs. incomplete vaccination). Janus kinase inhibitor (JAKi) pre-exposure significantly reduced the risk of severe COVID-19 in hospitalized patients (0.16, 0.04 to 0.74, 0.019, vs. csDMARDs). ASyS patients with severe COVID-19 had significantly reduced peripheral CD4+ T cells, lower CD4/CD8 ratio, and fewer naive B cells but more class-switched memory B cells compared with controls.ConclusionASyS and family oxygen supplement were first identified as risk factors for COVID-19-related hospitalization in patients with IIMs. JAKi pre-exposure might protect IIM patients against severe COVID-19 complications.

show abstract

“…Several studies suggested a potential correlation between onset or flares of IIM with COVID-19 infection and/or vaccination (30)(31)(32). Literature demonstrates a detrimental effect of the pandemic on continuity of care for many patients with IIM, raising concern for risk of downstream effects on disease outcomes for patients as well (33,34).…”

Section: Mental Health In Paediatric and Adult Myositis-related Disea...mentioning

confidence: 99%

Mental health in paediatric and adult myositis-related diseases: current state of research, interventions, and future steps from the MIHRA Psychological Impact Scientific Working Group

Lanis,

Alexanderson,

Ardalan

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Psychological and emotional well-being are critical aspects of overall health for individuals with chronic rheumatologic conditions. Mental health-related literature, however, predominantly focuses on systemic lupus erythematosus or rheumatoid arthritis, with limited emphasis on idiopathic inflammatory myopathies (IIMs). High proportions of those with juvenile myositis report psychological distress at levels warranting mental health referral. Adults with dermatomyositis diagnosed with depression or anxiety do not receive adequate mental health care. Mental health symptoms in those with IIMs are associated with worse health-related quality of life, medication adherence, and disease outcomes. Despite demonstrated high rates of mental health burden, access to mental health care remains severely lacking. Data related to mental health burden is limited by small sample size, limited generalisability, variable methods of assessment, and inconsistent diagnosis codes to define mental health conditions. Additional research is needed to validate current screening tools in myositis populations. Other relevant measurable factors include disease severity, non-health-and health-related trauma exposure, loneliness, isolation, loss of control, sleep difficulties, fatigue, pain, self-esteem, body image, sexual health, and health inequities. Studies are needed investigating the efficacy of therapeutic and pharmacologic interventions among patients with myositis

show abstract

Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience

Cited by 7 publications

References 22 publications

Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison?

Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison?

Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19

Mental health in paediatric and adult myositis-related diseases: current state of research, interventions, and future steps from the MIHRA Psychological Impact Scientific Working Group

Contact Info

Product

Resources

About